Host: HEK293 cells • AA: 1-419 (full length) • Tag: C-terminal DYKDDDDK • MW: 49.7 kDa
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

SARS-CoV-2 Nucleocapsid Protein

Item No. 30427

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Synonyms
  • 2019-nCoV NP
  • 2019-nCoV Nucleocapsid Protein
  • 2019-nCoV Nucleoprotein
  • COVID-19 NP
  • COVID-19 Nucleocapsid Protein
  • COVID-19 Nucleoprotein
  • SARS-CoV-2 NP
  • SARS-CoV-2 Nucleoprotein
  • Severe Acute Respiratory Syndrome Coronavirus 2 Nucleocapsid Protein
Purity
≥90% estimated by SDS-PAGE
Amino Acids
1-419 (full length)
MW
49.7 kDa
Storage Buffer
50 mM Tris-HCl, pH 7.4, with 150 mM sodium chloride and 0.1 M glycine
Shipping & Storage Information
Storage
-80°C
Shipping
Dry ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    50 µg

    $1,095

    Add
    Cayman Chemical
    Neutrophil Biology Wall Poster

    Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.

    DOWNLOAD NOW
    Product Description

    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid protein is a viral protein encoded by the N gene in SARS-CoV-2 RNA.1 SARS-CoV-2 is a member of the Betacoronavirus genus of viruses and has 88% sequence identity with two bat-derived SARS-like CoVs.2 SARS-CoV-2 nucleocapsid protein is composed of an N-terminal domain (NTD) that binds RNA, a disordered linker region that contains regulatory phosphorylation sites, a C-terminal domain (CTD) that mediates dimerization, and a C-terminal tail.3 In a similar virus, SARS-CoV, the nucleocapsid protein packages the viral RNA into a helical ribonucleoprotein (RNP) complex that is a template for viral replication.4 The SARS-CoV nucleocapsid protein is integral for viral self-assembly and is involved in cell cycle regulation. The SARS-CoV-2 nucleocapsid protein gene sequence is greater than 90% similar to the SARS-CoV nucleocapsid protein, and it contains 27 T cell epitopes that are identical to SARS-CoV T cell epitopes.5 SARS-CoV-2 nucleocapsid protein inhibits the formation of stress granules, which sequester viral factors and are involved in the host antiviral response.6 SARS-CoV-2 is the causative agent of COVID-19, a primarily respiratory illness characterized by fever, cough, and shortness of breath that can lead to life-threatening complications.7,8,9 Cayman’s SARS-CoV-2 Nucleocapsid Protein can be used as an antigen or for Western blot (WB), ELISA, protein-protein interaction studies, and other in vitro binding and in vivo functional assays.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Kandeel, M., Ibrahim, A., Fayez, M., et al. From SARS and MERS CoVs to SARS-CoV-2: Moving toward more biased codon usage in viral structural and nonstructural genes. J. Med. Virol. 92(6), 660-666 (2020).

    2. Lu, R., Zhao, X., Li, J., et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet 395(10224), 565-574 (2020).

    3. Zhang, B., Tian, J., Zhang, Q., et al. Comparing the nucleocapsid proteins of human coronaviruses: Structure, immunoregulation, vaccine, and targeted drug. Front. Mol. Biosci. 9, 761173 (2022).

    4. Chang, C.-K., Hou, M.-H., Chang, C.-F., et al. The SARS coronavirus nucleocapsid protein – Forms and functions. Antiviral Res. 103, 39-50 (2014).

    5. Ahmed, S.F., Quadeer, A.A., and McKay, M.R. Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses 12(3), E254 (2020).

    6. Zheng, Z.-Q., Wang, S.-Y., Xu, Z.-S., et al. SARS-CoV-2 nucleocapsid protein impairs stress granule formation to promote viral replication. Cell Discov. 7(1), 38 (2021).

    7. Meo, S.A., Alhowikan, A.M., Al-Khlaiwi, T., et al. Novel coronavirus 2019-nCoV: Prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV. Eur. Rev. Med. Pharmacol. Sci. 24(4), 2012-2019 (2020).

    8. Klok, F.A., Kruip, M.J.H.A., van der Meer, N.J.M., et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb. Res. 191, 145-147 (2020).

    9. Yang, F., Shi, S., Zhu, J., et al. Analysis of 92 deceased patients with COVID-19. J. Med. Virol. 92(11), 2511-2515 (2020).